C. Aninat, A. Piton, D. Glaise, L. Charpentier, T. Langouet et al., EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS, Drug Metabolism and Disposition, vol.34, issue.1, pp.75-83, 2006.
DOI : 10.1124/dmd.105.006759
URL : https://hal.archives-ouvertes.fr/hal-00702085

S. Antherieu, C. Chesne, R. Li, S. Camus, A. Lahoz et al., Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells, Drug Metabolism and Disposition, vol.38, issue.3, pp.516-525, 2010.
DOI : 10.1124/dmd.109.030197
URL : https://hal.archives-ouvertes.fr/hal-00741715

S. Antherieu, A. Rogue, B. Fromenty, A. Guillouzo, R. et al., Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells, Hepatology, vol.96, issue.Suppl., pp.1895-1905, 2011.
DOI : 10.1002/hep.24290
URL : https://hal.archives-ouvertes.fr/hal-00739358

B. Balas, R. Belfort, S. A. Harrison, C. Darland, J. Finch et al., Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.47, issue.4, pp.565-570, 2007.
DOI : 10.1016/j.jhep.2007.04.013

G. D. Barish, V. A. Narkar, and R. M. Evans, PPAR??: a dagger in the heart of the metabolic syndrome, Journal of Clinical Investigation, vol.116, issue.3, pp.590-597, 2006.
DOI : 10.1172/JCI27955

R. Belfort, S. A. Harrison, K. Brown, C. Darland, J. Finch et al., A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis, New England Journal of Medicine, vol.355, issue.22, pp.2297-2307, 2006.
DOI : 10.1056/NEJMoa060326

J. Borg, C. Klint, N. Wierup, K. Strom, S. Larsson et al., Perilipin Is Present in Islets of Langerhans and Protects against Lipotoxicity When Overexpressed in the ??-Cell Line INS-1, Endocrinology, vol.150, issue.7, pp.3049-3057, 2009.
DOI : 10.1210/en.2008-0913

S. Caldwell and C. Argo, The Natural History of Non-Alcoholic Fatty Liver Disease, Digestive Diseases, vol.28, issue.1, pp.162-168, 2010.
DOI : 10.1159/000282081

V. Cerec, D. Glaise, D. Garnier, S. Morosan, B. Turlin et al., Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor, Hepatology, vol.103, issue.4, pp.957-967, 2007.
DOI : 10.1002/hep.21536
URL : https://hal.archives-ouvertes.fr/hal-00690471

H. Chen, B. Dardik, L. Qiu, X. Ren, S. L. Caplan et al., Cevoglitazar, a Novel Peroxisome Proliferator-Activated Receptor-??/?? Dual Agonist, Potently Reduces Food Intake and Body Weight in Obese Mice and Cynomolgus Monkeys, Endocrinology, vol.151, issue.7, pp.3115-3124, 2010.
DOI : 10.1210/en.2009-1366

R. Deehan, P. Maerz-weiss, N. L. Catlett, G. Steiner, B. Wong et al., Comparative Transcriptional Network Modeling of Three PPAR-??/?? Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes, PLoS ONE, vol.32, issue.4, p.35012, 2012.
DOI : 10.1371/journal.pone.0035012.g007

B. Desvergne, L. Michalik, and W. Wahli, Transcriptional Regulation of Metabolism, Physiological Reviews, vol.86, issue.2, pp.465-514, 2006.
DOI : 10.1152/physrev.00025.2005

B. Dong, P. K. Saha, W. Huang, W. Chen, L. A. Abu-elheiga et al., Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease, Proceedings of the National Academy of Sciences, vol.106, issue.44, pp.18831-18836, 2009.
DOI : 10.1073/pnas.0909731106

H. Ericsson, B. Hamren, S. Bergstrand, M. Elebring, L. Fryklund et al., Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans, Drug Metab Dispos, vol.32, pp.923-929, 2004.

C. Y. Fan, J. Pan, R. Chu, D. Lee, K. D. Kluckman et al., Targeted Disruption of the Peroxisomal Fatty Acyl-CoA Oxidase Gene: Generation of a Mouse Model of Pseudoneonatal Adrenoleukodystrophy, Annals of the New York Academy of Sciences, vol.15, issue.1 Peroxisomes, pp.530-541, 1996.
DOI : 10.1074/jbc.271.44.27237

M. Fernandez, A. Gastaldelli, C. Triplitt, J. Hardies, A. Casolaro et al., Metabolic effects of muraglitazar in type 2 diabetic subjects, Diabetes, Obesity and Metabolism, vol.347, issue.(Suppl 3), pp.893-902, 2011.
DOI : 10.1111/j.1463-1326.2011.01429.x

C. Fievet, J. C. Fruchart, and B. Staels, PPAR?? and PPAR?? dual agonists for the treatment of type 2 diabetes and the metabolic syndrome, Current Opinion in Pharmacology, vol.6, issue.6, pp.606-614, 2006.
DOI : 10.1016/j.coph.2006.06.009

C. Fisch, M. A. Robin, P. Letteron, B. Fromenty, A. Berson et al., Cell-generated nitric oxide inactivates rat hepatocyte mitochondria in vitro but reacts with hemoglobin in vivo, Gastroenterology, vol.110, issue.1, pp.210-220, 1996.
DOI : 10.1053/gast.1996.v110.pm8536859

O. Gavrilova, M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson et al., Liver Peroxisome Proliferator-activated Receptor ?? Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass, Journal of Biological Chemistry, vol.278, issue.36, pp.34268-34276, 2003.
DOI : 10.1074/jbc.M300043200

J. George and C. Liddle, Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets, Molecular Pharmaceutics, vol.5, issue.1, pp.49-59, 2008.
DOI : 10.1021/mp700110z

P. Gripon, S. Rumin, S. Urban, L. Seyec, J. Glaise et al., Nonlinear partial differential equations and applications: Infection of a human hepatoma cell line by hepatitis B virus, Proceedings of the National Academy of Sciences, vol.99, issue.24, pp.15655-15660, 2002.
DOI : 10.1073/pnas.232137699

B. Hamren, H. Ericsson, O. Samuelsson, and M. O. Karlsson, Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function ??? evidence of interconversion, British Journal of Clinical Pharmacology, vol.6, issue.6, pp.855-863, 2008.
DOI : 10.1016/0163-7258(90)90036-2

C. D. Kane, O. L. Francone, and K. A. Stevens, Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPAR??, Gene, vol.380, issue.2, pp.84-94, 2006.
DOI : 10.1016/j.gene.2006.05.011

K. P. Kanebratt and T. B. Andersson, Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies, Drug Metabolism and Disposition, vol.36, issue.7, pp.1444-1452, 2008.
DOI : 10.1124/dmd.107.020016

J. B. Kim, H. M. Wright, M. Wright, and B. M. Spiegelman, ADD1/SREBP1 activates PPAR?? through the production of endogenous ligand, Proceedings of the National Academy of Sciences, vol.95, issue.8, pp.4333-4337, 1998.
DOI : 10.1073/pnas.95.8.4333

J. Laurin, K. D. Lindor, J. S. Crippin, A. Gossard, G. J. Gores et al., Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study, Hepatology, vol.23, issue.6, pp.1464-1467, 1996.
DOI : 10.1002/hep.510230624

H. J. Lim, J. H. Park, S. Lee, H. E. Choi, K. S. Lee et al., PPAR?? ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR???/??? mice, European Journal of Pharmacology, vol.622, issue.1-3, pp.45-51, 2009.
DOI : 10.1016/j.ejphar.2009.09.002

R. Lomonaco, N. E. Sunny, F. Bril, C. , and K. , Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches, Drugs, vol.53, issue.6, pp.1-14, 2013.
DOI : 10.1007/s40265-012-0004-0

S. E. Mahady, A. C. Webster, S. Walker, A. Sanyal, G. et al., The role of thiazolidinediones in non-alcoholic steatohepatitis ??? A systematic review and meta analysis, Journal of Hepatology, vol.55, issue.6, pp.1383-1390, 2011.
DOI : 10.1016/j.jhep.2011.03.016

L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass et al., International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors, Pharmacological Reviews, vol.58, issue.4, pp.726-741, 2006.
DOI : 10.1124/pr.58.4.5
URL : https://hal.archives-ouvertes.fr/hal-00188041

D. B. Miller, S. , and J. D. , Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates), Clinical Pharmacokinetics, vol.34, issue.2, 1998.
DOI : 10.2165/00003088-199834020-00003

E. Moran-salvador, M. Lopez-parra, V. Garcia-alonso, E. Titos, M. Martinez-clemente et al., Role for PPAR?? in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts, The FASEB Journal, vol.25, issue.8, pp.2538-2550, 2011.
DOI : 10.1096/fj.10-173716

M. Moya, M. J. Gomez-lechon, J. V. Castell, and R. Jover, Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile, Chemico-Biological Interactions, vol.184, issue.3, pp.376-387, 2010.
DOI : 10.1016/j.cbi.2010.01.008

G. Musso, R. Gambino, M. Cassader, and G. Pagano, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology, vol.51, issue.Supplement DDW, pp.79-104, 2010.
DOI : 10.1002/hep.23623

Y. Nagai, Y. Nishio, T. Nakamura, H. Maegawa, R. Kikkawa et al., Amelioration of high fructose-induced metabolic derangements by activation of PPAR??, American Journal of Physiology - Endocrinology And Metabolism, vol.282, issue.5, pp.1180-1190, 2002.
DOI : 10.1152/ajpendo.00471.2001

T. Nagasawa, Y. Inada, S. Nakano, T. Tamura, T. Takahashi et al., Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR?? agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet, European Journal of Pharmacology, vol.536, issue.1-2, pp.182-191, 2006.
DOI : 10.1016/j.ejphar.2006.02.028

V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-heurtier et al., Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, vol.135, issue.1, pp.100-110, 2008.
DOI : 10.1053/j.gastro.2008.03.078

J. K. Reddy and T. Hashimoto, ??: An Adaptive Metabolic System, Annual Review of Nutrition, vol.21, issue.1, pp.193-230, 2001.
DOI : 10.1146/annurev.nutr.21.1.193

A. Rogue, C. Lambert, R. Josse, S. Antherieu, C. Spire et al., Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in human hepatocytes, PLoS One, vol.6, 2011.

C. J. Rubin, K. Viraswami-appanna, and F. T. Fiedorek, Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes, Diabetes and Vascular Disease Research, vol.11, issue.3, pp.205-215, 2009.
DOI : 10.1177/1479164109336048

A. J. Scheen, Pharmacokinetic Interactions with Thiazolidinediones, Clinical Pharmacokinetics, vol.63, issue.12, pp.1-12, 2007.
DOI : 10.2165/00003088-200746010-00001

J. R. Simard, T. Meshulam, B. K. Pillai, M. T. Kirber, K. Brunaldi et al., Caveolins sequester FA on the cytoplasmic leaflet of the plasma membrane, augment triglyceride formation, and protect cells from lipotoxicity, The Journal of Lipid Research, vol.51, issue.5, pp.914-922, 2010.
DOI : 10.1194/jlr.M900251

S. Tonstad, K. Retterstol, L. Ose, K. P. Ohman, M. B. Lindberg et al., The dual peroxisome proliferator???activated receptor ??/?? agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin, Metabolism, vol.56, issue.9, pp.1285-1292, 2007.
DOI : 10.1016/j.metabol.2007.05.003

A. Vluggens, P. Andreoletti, N. Viswakarma, Y. Jia, K. Matsumoto et al., Functional significance of the two ACOX1 isoforms and their crosstalks with PPAR?? and RXR??, Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform, pp.696-708, 2010.
DOI : 10.1128/MCB.20.12.4436-4444.2000

L. Wang, D. Zhang, A. Swaminathan, Y. Xue, P. T. Cheng et al., Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection, Drug Metab Dispos, vol.34, pp.427-439, 2006.

Y. X. Wang, C. H. Lee, S. Tiep, R. T. Yu, J. Ham et al., Peroxisome-Proliferator-Activated Receptor ?? Activates Fat Metabolism to Prevent Obesity, Cell, vol.113, issue.2, pp.159-170, 2003.
DOI : 10.1016/S0092-8674(03)00269-1

M. Watanabe, S. M. Houten, L. Wang, A. Moschetta, D. J. Mangelsdorf et al., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c, Journal of Clinical Investigation, vol.113, issue.10, pp.1408-1418, 2004.
DOI : 10.1172/JCI21025

J. M. Ye, G. Frangioudakis, M. A. Iglesias, S. M. Furler, B. Ellis et al., Prior Thiazolidinedione Treatment Preserves Insulin Sensitivity in Normal Rats during Acute Fatty Acid Elevation: Role of the Liver, Endocrinology, vol.143, issue.12, pp.4527-4535, 2002.
DOI : 10.1210/en.2002-220387

B. C. Zhang, W. M. Li, X. K. Li, M. Y. Zhu, W. L. Che et al., Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice, Exp Ther Med, vol.4, pp.987-992, 2012.

Y. Zhang, L. W. Castellani, C. J. Sinal, F. J. Gonzalez, and P. A. Edwards, Peroxisome proliferator-activated receptor-?? coactivator 1?? (PGC-1??) regulates triglyceride metabolism by activation of the nuclear receptor FXR, Genes & Development, vol.18, issue.2, pp.157-169, 2004.
DOI : 10.1101/gad.1138104